Krilogy Financial LLC Purchases New Holdings in Medpace Holdings, Inc. $MEDP

Krilogy Financial LLC acquired a new position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) in the third quarter, according to its most recent disclosure with the SEC. The firm acquired 3,164 shares of the company’s stock, valued at approximately $1,627,000.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Quent Capital LLC purchased a new stake in shares of Medpace during the 3rd quarter worth $25,000. Geneos Wealth Management Inc. lifted its stake in shares of Medpace by 64.9% in the first quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock valued at $29,000 after purchasing an additional 37 shares during the period. Employees Retirement System of Texas purchased a new stake in Medpace during the second quarter worth about $36,000. Root Financial Partners LLC purchased a new stake in Medpace during the third quarter worth about $38,000. Finally, Whittier Trust Co. of Nevada Inc. grew its position in Medpace by 35.1% during the third quarter. Whittier Trust Co. of Nevada Inc. now owns 104 shares of the company’s stock worth $55,000 after buying an additional 27 shares during the period. 77.98% of the stock is currently owned by hedge funds and other institutional investors.

Medpace Stock Performance

Medpace stock opened at $423.93 on Thursday. Medpace Holdings, Inc. has a fifty-two week low of $250.05 and a fifty-two week high of $628.92. The company has a market capitalization of $11.94 billion, a price-to-earnings ratio of 27.71, a PEG ratio of 1.45 and a beta of 1.42. The stock has a fifty day moving average of $572.49 and a two-hundred day moving average of $538.75.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings data on Monday, February 9th. The company reported $4.67 EPS for the quarter, beating analysts’ consensus estimates of $4.18 by $0.49. Medpace had a return on equity of 118.82% and a net margin of 17.83%.The business had revenue of $708.45 million for the quarter, compared to analyst estimates of $689.53 million. During the same quarter last year, the company earned $3.67 earnings per share. The business’s revenue for the quarter was up 32.0% compared to the same quarter last year. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. On average, analysts forecast that Medpace Holdings, Inc. will post 12.29 EPS for the current fiscal year.

Key Headlines Impacting Medpace

Here are the key news stories impacting Medpace this week:

• Positive Sentiment: Company beat Q4 revenue and EPS estimates and provided FY2026 EPS guidance (16.68–17.50), showing continued underlying growth momentum. Medpace (NASDAQ:MEDP) Reports Bullish Q4 CY2025
• Positive Sentiment: Medpace was selected as CRO by Zelluna for the ZIMA‑101 first‑in‑human trial — a business win that expands clinical services revenue opportunity. Zelluna selects Medpace as CRO
• Positive Sentiment: Robert W. Baird upgraded the stock to “outperform” with a $564 price target, signaling some analysts still see meaningful upside. Baird upgrade
• Neutral Sentiment: Earnings call transcript and presentation are available for investors digging into management’s remarks on backlog, book‑to‑bill and trial mix to judge forward revenue trajectory. Earnings call transcript
• Negative Sentiment: Several firms cut targets/ratings this morning — Barclays moved to “underweight” and trimmed its target to $500, Leerink lowered its target to $485 (market perform), and Truist cut to a $539 target with a “hold.” Those changes increase near‑term selling pressure. Analyst target changes Truist note
• Negative Sentiment: Market reaction focused on management’s comments about backlog normalization and trial‑mix shifts (metabolic trials), which tempered revenue growth expectations despite the beat — headlines flagged this as the “key negative.” Backlog normalization story
• Negative Sentiment: Coverage noted the stock dropped despite the beat, reflecting short‑term profit taking and concern that a strong quarter may already be priced in. Shares tumble despite beat

Insider Activity

In other news, VP Susan E. Burwig sold 20,000 shares of the business’s stock in a transaction dated Monday, November 24th. The stock was sold at an average price of $609.15, for a total transaction of $12,183,000.00. Following the completion of the sale, the vice president owned 27,500 shares in the company, valued at approximately $16,751,625. The trade was a 42.11% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO August J. Troendle sold 59,025 shares of the stock in a transaction on Monday, November 24th. The stock was sold at an average price of $607.78, for a total transaction of $35,874,214.50. Following the completion of the sale, the chief executive officer directly owned 774,602 shares of the company’s stock, valued at $470,787,603.56. The trade was a 7.08% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 291,752 shares of company stock worth $175,731,579. Insiders own 20.30% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on MEDP shares. Weiss Ratings reiterated a “buy (b)” rating on shares of Medpace in a research report on Wednesday, January 28th. Wall Street Zen raised Medpace from a “hold” rating to a “buy” rating in a report on Saturday, January 17th. Truist Financial decreased their target price on Medpace from $555.00 to $539.00 and set a “hold” rating on the stock in a research report on Wednesday. Barclays lowered their target price on Medpace from $525.00 to $500.00 and set an “underweight” rating on the stock in a report on Wednesday. Finally, Zacks Research downgraded Medpace from a “strong-buy” rating to a “hold” rating in a research note on Monday, January 12th. Three analysts have rated the stock with a Buy rating, eight have issued a Hold rating and three have issued a Sell rating to the company’s stock. According to MarketBeat, Medpace has a consensus rating of “Hold” and an average price target of $477.36.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.